Evidence map›Paper›PMID 37633886›Full record

ReviewCancer cell international2023

3,3'-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways.

Octavio Daniel Reyes-Hernández, Gabriela Figueroa-González, Laura Itzel Quintas-Granados, Stephany Celeste Gutiérrez-Ruíz, Hector Hernández-Parra, Alejandra Romero-Montero, María Luisa Del Prado-Audelo, Sergio Alberto Bernal-Chavez, Hernán Cortés, Sheila I Peña-Corona and 5 more

Abstract readReview
In one paragraph

Review in Cancer cell international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Review
  2. Review
  3. Glucosinolate Derivatives: Emerging Anti-Inflammatory Agents.Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Antivirulence drugs against Acinetobacter baumannii: where do they stand?World journal of microbiology & biotechnology · 2025
    Review
  13. Review
  14. Article
  15. Targeting gut microbiota and metabolites in cancer radiotherapy.Clinical and translational medicine · 2025
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Octavio Daniel Reyes-HernándezLaboratorio de Biología Molecular del Cáncer, Facultad de Estudios Superiores Zaragoza, UMIEZ, Universidad Nacional Autónoma de México, Ciudad de México, 09230, Mexico.
Gabriela Figueroa-GonzálezLaboratorio de Farmacogenética, Facultad de Estudios Superiores Zaragoza, UMIEZ, Universidad Nacional Autónoma de México, Ciudad de México, 09230, Mexico.
Laura Itzel Quintas-GranadosUniversidad Mexiquense del Bicentenario, Unidad de Estudios Superiores Tultitlán, Mexico, Mexico.
Stephany Celeste Gutiérrez-RuízDepartamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, 04510, Mexico.
Hector Hernández-ParraDepartamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, 04510, Mexico.
Alejandra Romero-MonteroDepartamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, 04510, Mexico.
María Luisa Del Prado-AudeloEscuela de Ingeniería y Ciencias, Tecnologico de Monterrey, Campus Ciudad de México, C. Puente 222, Ciudad de México, 14380, Mexico.
Sergio Alberto Bernal-ChavezDepartamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, 04510, Mexico.
Hernán CortésLaboratorio de Medicina Genómica, Departamento de Genómica, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Ciudad de Mexico, Mexico.
Sheila I Peña-CoronaDepartamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, 04510, Mexico.
Lashyn KiyekbayevaPharmaceutical School, Department of Pharmaceutical Technology, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Dilek Arslan AteşşahinBaskil Vocational School, Department of Plant and Animal Production, Fırat University, Elazıg, 23100, Turkey.
Tamar GoloshviliDepartment of Plant Physiology and Genetic Resources, Institute of Botany, Ilia State University, Tbilisi, 0162, Georgia.
Gerardo Leyva-GómezDepartamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, 04510, Mexico. leyva@quimica.unam.mx.
Javad Sharifi-RadFacultad de Medicina, Universidad del Azuay, Cuenca, Ecuador. javad.sharifirad@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dietary compounds in cancer prevention have gained significant consideration as a viable method. Indole-3-carbinol (I3C) and 3,3'-diindolylmethane (DIM) are heterocyclic and bioactive chemicals found in cruciferous vegetables like broccoli, cauliflower, cabbage, and brussels sprouts. They are synthesized after glycolysis from the glucosinolate structure. Clinical and preclinical trials have evaluated the pharmacokinetic/pharmacodynamic, effectiveness, antioxidant, cancer-preventing (cervical dysplasia, prostate cancer, breast cancer), and anti-tumor activities of I3C and DIM involved with polyphenolic derivatives created in the digestion showing promising results. However, the exact mechanism by which they exert anti-cancer and apoptosis-inducing properties has yet to be entirely understood. Via this study, we update the existing knowledge of the state of anti-cancer investigation concerning I3C and DIM chemicals. We have also summarized; (i) the recent advancements in the use of I3C/DIM as therapeutic molecules since they represent potentially appealing anti-cancer agents, (ii) the available literature on the I3C and DIM characterization, and the challenges related to pharmacologic properties such as low solubility, and poor bioavailability, (iii) the synthesis and semi-synthetic derivatives, (iv) the mechanism of anti-tumor action in vitro/in vivo, (v) the action in cellular signaling pathways related to the regulation of apoptosis and anoikis as well as the cell cycle progression and cell proliferation such as peroxisome proliferator-activated receptor and PPARγ agonists; SR13668, Akt inhibitor, cyclins regulation, ER-dependent-independent pathways, and their current medical applications, to recognize research opportunities to potentially use these compounds instead chemotherapeutic synthetic drugs.

Indexed as

3,3'-diindolylmethane (DIM)Anti-tumor actionCancerChemotherapeutic drugsIndole-3-carbinol (I3C)

Identifiers

PMID37633886
PMCPMC10464192

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.